clinical efficacy and safety of tenofovir disoproxil fumarate and entcavir in treatment of chronic hepatitis b patients in upper egypt

Conditions: Chronic Hepatitis b Patients

Summary: chronic hepatitis b (chb) is one of the major causes of chronic liver diseases worldwide. around 296 million people were living with chronic hepatitis b infection, with 1.5 million new infections each year and more than 820 thousand people die because of hepatitis b virus (hbv) related complications

chronic hepatitis b is a long-term liver disease. the disease is often characterized by abnormal levels of serum alt and ast, as well as liver histology, and is transmitted through blood, sexual contact, and mother-to-child transmission. the symptoms of chb include fatigue, nausea, abdominal distension, and rt hypochondrial pain, and in severe cases, it can be accompanied by chronic liver disease, spider nevus, abnormal liver function, or persistent abnormality. the progression of hepatitis b virus (hbv) is closely linked to its replication, and the most effective way to prevent it is through hepatitis b vaccination. however, there is currently no specific drug available to eliminate the virus in patients with chronic hepatitis b (chb) due to the low rate of hbsag clearance. instead, primary treatment methods for chb aim to inhibit virus replication for an extended period and delay the onset of liver cirrhosis and hepatocellular carcinoma. antiviral, liver protection, antifibrosis, and immunomodulatory therapies are used to achieve this goal. among these therapies, nucleoside (acid) analogs (na) are commonly used, with drugs such as entecavir (etv) and tenofovir (tdf) being the most effective. tenofovir is a new type of nucleotide reverse transcriptase inhibitor, which inhibits reverse transcriptase similarly to nucleoside reverse transcriptase inhibitors. to a certain extent, it can reduce transaminase, protect the liver, and has a good effect on the treatment of hepatitis b. etv is a carboxylic analog of 2'-deoxyguanosine, which inhibits hbv dna polymerase by competing with natural deoxy guanosine triphosphate. the use of entecavir (etv) and tenofovir disoproxil (tdf) are both effective in managing hepatitis b virus (hbv) infection, and are well-tolerated by most patients. while there are no significant differences in the ability of the various treatments to suppress the virus, some studies suggest that tdf may achieve biochemical response more quickly. nucleoside analogs with a high barrier to resistance are unlikely to lead to the clearance of hepatitis b surface antigen, and should therefore be continued for most patients throughout their lifetime. however, there are concerns about the potential for toxicity with tdf in patients who have additional risk factors for kidney and bone problems. it is important to monitor for adverse effects, and switching to etv may be a safe and effective alternative for patients with hbv. although effective antiviral treatment can improve the clinical outcome of chronic hbv patients, there is still a risk of developing hepatocellular carcinoma (hcc) even with viral suppression. it is unclear whether tdf-based regimens offer any additional benefits over etv in preventing hcc, and more research is needed in this area. studies conducted on both tdf and etv have demonstrated their safety in both pivotal trials and real-life cohorts. in less than 10% of cases, mild side effects such as headache, fatigue, dizziness, nausea, abdominal discomfort, and nasopharyngitis have been reported for both drugs. these side effects are generally temporary and not severe enough to require discontinuation of treatment. however, tdf has been associated with kidney dysfunction, particularly in patients with pre-existing kidney disease or other risk factors for renal impairment. furthermore, tdf has been linked to bone disease. as a result, the european association for the study of the liver recommends selecting or switching to etv for patients with chronic hepatitis b who are at greater risk of bone and kidney toxicity.

Eligibility criteria:
inclusion criteria: * patient with hbsag positivity for at least 6 months. * patients have hbeag positive or negative. * patient recived theryapy with etv 0.5 or 1 mg/day or tdf 300 mg/day. * patients have regular monitoring every 6 months. exclusion criteria: * patients younger than 18 years old. * patients co-infected with hepatitis c, hepatitis d. * patients receiving immune suppressive therapy or with history of immunodeficiency